Patents by Inventor Melissa K. Thomas
Melissa K. Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240074677Abstract: A monitoring apparatus and method includes a monitor, a sensor comprising a wireless connection with the monitor, and an adapter comprising the wireless connection with the monitor and a wired or wireless connection with a remote monitoring station. The monitor is designed to wirelessly pair with the sensor and/or the adapter when being only positioned by a user in a closed proximity to the sensor and/or the adapter or in a direct contact with the sensor and/or the adapter and without an additional action by the user and/or a wired connection between the monitor and the sensor and/or the adapter. A pairing alignment mark may be provided on each of the monitor, sensor and adapter.Type: ApplicationFiled: November 10, 2023Publication date: March 7, 2024Applicant: TIDI Products, LLCInventors: Justin K. Thomas, Samantha L. McCarthy, Eduardo Hernandez, Brian Nathan Young, Melissa Waldroup, Joe Samz
-
Patent number: 8110399Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin and/or ABCG2-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: GrantFiled: May 22, 2006Date of Patent: February 7, 2012Assignee: The General Hospital CorporationInventors: Joel F. Habener, Henryk Zulewski, Melissa K. Thomas, Elizabeth J. Abraham, Mario Vallejo, Colin A. Leech, Anna Louise Nolan, Andreas Lechner
-
Patent number: 7875275Abstract: The present invention is directed to the use of Bridge-1 polynucleotides and Bridge-1 polypeptides, as well as activators and inhibitors of Bridge-1 activity, in the treatment of Bridge-1 mediated disorders, including diabetes.Type: GrantFiled: June 16, 2005Date of Patent: January 25, 2011Assignee: The General Hospital CorporationInventors: Constanze Banz, Joel F. Habener, Melissa K. Thomas
-
Patent number: 7632812Abstract: The invention features a method of treating deficiency of insulin in a patient, comprising administering to a patient in need thereof hedgehog protein or nucleic acid in an amount effective to raise the level of insulin in the patient.Type: GrantFiled: April 14, 2005Date of Patent: December 15, 2009Assignee: Massachusetts General HospitalInventors: Joel F Habener, Melissa K. Thomas
-
Patent number: 7544510Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: GrantFiled: April 24, 2006Date of Patent: June 9, 2009Assignee: The General Hospital CorporationInventors: Joel F. Habener, Elizabeth J. Abraham, Henryk Zulewski, Melissa K. Thomas, Mario Vallejo
-
Publication number: 20090138978Abstract: The present invention is directed to the use of Bridge-1 polynucleotides and Bridge-1 polypeptides, as well as activators and inhibitors of Bridge-1 activity, in the treatment of Bridge-1 mediated disorders, including diabetes.Type: ApplicationFiled: June 16, 2005Publication date: May 28, 2009Inventors: Constanze Banz, Joel F. Habener, Melissa K. Thomas
-
Patent number: 7537756Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: GrantFiled: May 19, 2005Date of Patent: May 26, 2009Assignee: The General Hospital CorporationInventors: Joel E. Habener, Hendrik Zulewski, Elizabeth J. Abraham, Mario Vallejo, Denise L. Faustman, Melissa K. Thomas
-
Patent number: 7438902Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: GrantFiled: November 9, 2004Date of Patent: October 21, 2008Assignee: The General Hospital CorporationInventors: Joel E. Habener, Henryk Zulewski, Elizabeth J. Abraham, Mario Vallejo, Denise L. Faustman, Melissa K. Thomas
-
Patent number: 6923959Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: GrantFiled: May 2, 2002Date of Patent: August 2, 2005Assignee: The General Hospital CorporationInventors: Joel F. Habener, Henryk Zulewski, Elizabeth J. Abraham, Mario Vallejo, Denise L. Faustman, Melissa K. Thomas
-
Patent number: 6903073Abstract: The invention features a method of treating deficiency of insulin in a patient, comprising administering to a patient in need thereof hedgehog protein or nucleic acid in an amount effective to raise the level of insulin in the patient.Type: GrantFiled: December 8, 2000Date of Patent: June 7, 2005Assignee: The General Hospital CorporationInventors: Joel F. Habener, Melissa K. Thomas
-
Patent number: 6866843Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: GrantFiled: December 6, 2000Date of Patent: March 15, 2005Assignee: Viacell, Inc.Inventors: Joel F. Habener, Henryk Zulewski, Elizabeth Abraham, Mario Vallejo, Denise L. Faustman, Melissa K. Thomas
-
Publication number: 20030082155Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin and/or ABCG2-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: April 11, 2002Publication date: May 1, 2003Inventors: Joel F. Habener, Henryk Zulewski, Melissa K. Thomas, Elizabeth J. Abraham, Mario Vallejo, Colin A. Leech, Anna Louise Nolan, Andreas Lechner
-
Publication number: 20030054992Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.Type: ApplicationFiled: April 3, 2002Publication date: March 20, 2003Applicant: ICOS CorporationInventors: Joseph A. Beavo, Jackie D. Corbin, Kenneth M. Ferguson, Sharron H. Francis, Ann Kadlecek, Kate Loughney, Linda M. McAllister-Lucas, William K. Sonnenburg, Melissa K. Thomas
-
Publication number: 20030031657Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: May 2, 2002Publication date: February 13, 2003Applicant: Massachusetts General HospitalInventors: Joel F. Habener, Henryk Zulewski, Elizabeth J. Abraham, Mario Vallejo, Denise L. Faustman, Melissa K. Thomas
-
Publication number: 20030013646Abstract: The invention features a method of treating deficiency of insulin in a patient, comprising administering to a patient in need thereof hedgehog protein or nucleic acid in an amount effective to raise the level of insulin in the patient.Type: ApplicationFiled: December 8, 2000Publication date: January 16, 2003Inventors: Joel F. Habener, Melissa K. Thomas
-
Publication number: 20020164307Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and GLP-1 receptor have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby stem cells which express one or both of nestin and GLP-1R can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed.Type: ApplicationFiled: September 26, 2001Publication date: November 7, 2002Inventors: Joel F. Habener, Henryk Zulewski, Melissa K. Thomas, Elizabeth J. Abraham, Mario Vallejo, Colin A. Leech
-
Publication number: 20010046489Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: December 6, 2000Publication date: November 29, 2001Inventors: Joel E. Habener, Henryk Zulewski, Elizabeth J. Abraham, Melissa K. Thomas, Mario Vallejo
-
Patent number: 6037119Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.Type: GrantFiled: June 5, 1995Date of Patent: March 14, 2000Assignee: Board of Regents of the University of WashingtonInventors: Joseph A. Beavo, Jackie D. Corbin, Kenneth M. Ferguson, Sharron H. Francis, Ann Kadlecek, Kate Loughney, Linda M. McAllister-Lucas, William K. Sonnenburg, Melissa K. Thomas
-
Patent number: 5955583Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Antibodies to the cGMP-binding, cGMP-stimulated phosphodiesterase are disclosed. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.Type: GrantFiled: June 5, 1995Date of Patent: September 21, 1999Assignees: ICOS Corporation, Board of Regents of the University of Washington, Vanderbilt UniversityInventors: Joseph A. Beavo, Jackie D. Corbin, Kenneth M. Ferguson, Sharron H. Francis, Ann Kadlecek, Kate Loughney, Linda M. McAllister-Lucas, William K. Sonnenburg, Melissa K. Thomas
-
Patent number: 5702936Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.Type: GrantFiled: May 27, 1994Date of Patent: December 30, 1997Assignees: ICOS Corporation, Vanderbilt University, Board of Regents of the University of WashingtonInventors: Joseph A. Beavo, Jackie D. Corbin, Kenneth M. Ferguson, Sharron H. Francis, Ann Kadlecek, Kate Loughney, Linda M. McAllister-Lucas, William K. Sonnenburg, Melissa K. Thomas